Providing alternatives to patients with genetic predispositions to cancer and therapy-resistant cancers
Trocar Oncology's innovator, small molecule oncology medicines treat breast, ovarian and prostate cancers.
Our oncology drug priority areas include providing therapeutic alternatives to women with BRCA-1 mutations and Tamoxifen-resistant cancers.
BRCA-1 Mutation & Breast Cancer
Mutations (inherited defects) of the BRCA-1 gene lead to breast cancer in 55-65% of women. The incidence of breast cancer in women with the BRCA1 gene mutation is 6x higher compared to the general population.
Tamoxifen and aromatase inhibitors have made a significant impact in the treatment of breast cancer; however, there is a great need for new drugs for estrogen receptor positive (ER+) breast cancers.
About 50% of women with advanced breast cancer who receive the first line agent Tamoxifen fail to respond. Nearly all patients with metastatic breast cancer develop drug resistance and die of the disease. In addition, 40% of patients who receive Tamoxifen as an adjunct for earlier stage disease will acquire resistance during treatment and die.
Trocar's novel, patented BRCA-1 mimetic is a therapeutic for the treatment of BRCA (-) as well as Tamoxifen-resistant cancers. By binding to the estrogen receptor in the same manner of BRCA-1, our BRCA-1 mimetic inhibits ERα activity in breast and ovarian cancer cells and blocks estrogen (E2)-stimulated gene expression and cell proliferation.
Our small molecule BRCA-1 therapeutic also has application in the treatment of Tamoxifen-resistant patients as it uses a separate chemical pathway.
Trocar Oncology is partnering with the University of Minnesota, George Mason University and the University of Oklahoma on the development of its BRCA-1 mimetics.